相似文献
1
Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).
Int J Epidemiol. 2022 Jun 13;51(3):e73-e86. doi: 10.1093/ije/dyab211.
2
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
3
Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3).
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):200-207. doi: 10.1158/1055-9965.EPI-19-0734. Epub 2019 Nov 12.
4
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.
Cancer Res. 2019 Oct 15;79(20):5442-5451. doi: 10.1158/0008-5472.CAN-19-1554. Epub 2019 Aug 28.
5
Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
6
Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
Gynecol Oncol. 2019 Jun;153(3):589-596. doi: 10.1016/j.ygyno.2019.03.243. Epub 2019 Mar 21.
7
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).
Cancer Res. 2020 Mar 1;80(5):1210-1218. doi: 10.1158/0008-5472.CAN-19-2850. Epub 2020 Jan 13.
8
Ovarian cancer epidemiology in the era of collaborative team science.
Cancer Causes Control. 2017 May;28(5):487-495. doi: 10.1007/s10552-017-0862-6. Epub 2017 Mar 10.
9
Investigation of mammographic breast density as a risk factor for ovarian cancer.
J Natl Cancer Inst. 2014 Jan;106(1):djt341. doi: 10.1093/jnci/djt341. Epub 2013 Dec 5.
10
Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort.
Int J Oncol. 2012 Jan;40(1):21-30. doi: 10.3892/ijo.2011.1194. Epub 2011 Sep 8.
引用本文的文献
1
Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis.
BMC Cancer. 2025 Feb 26;25(1):355. doi: 10.1186/s12885-025-13652-9.
2
Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.
Cancer Epidemiol Biomarkers Prev. 2024 Oct 2;33(10):1347-1355. doi: 10.1158/1055-9965.EPI-24-0319.
3
Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer.
Cell Rep Med. 2024 Jul 16;5(7):101612. doi: 10.1016/j.xcrm.2024.101612. Epub 2024 Jun 14.
4
Quantifiable TCR repertoire changes in pre-diagnostic blood specimens among high-grade ovarian cancer patients.
bioRxiv. 2023 Oct 17:2023.10.12.562056. doi: 10.1101/2023.10.12.562056.
5
The relationship of lifetime history of depression on the ovarian tumor immune microenvironment.
Brain Behav Immun. 2023 Nov;114:52-60. doi: 10.1016/j.bbi.2023.08.006. Epub 2023 Aug 7.
6
Time spent in the sun and the risk of developing non-Hodgkin lymphoma: a Canadian cohort study.
Cancer Causes Control. 2023 Sep;34(9):791-799. doi: 10.1007/s10552-023-01719-6. Epub 2023 Jun 1.
7
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
J Clin Oncol. 2022 Dec 20;40(36):4207-4217. doi: 10.1200/JCO.21.01900. Epub 2022 Jul 22.
本文引用的文献
1
Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2010-2018. doi: 10.1158/1055-9965.EPI-20-0354. Epub 2020 Jul 30.
2
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Clin Cancer Res. 2020 Oct 15;26(20):5411-5423. doi: 10.1158/1078-0432.CCR-20-0103. Epub 2020 Jun 17.
3
Prognostic gene expression signature for high-grade serous ovarian cancer.
Ann Oncol. 2020 Sep;31(9):1240-1250. doi: 10.1016/j.annonc.2020.05.019. Epub 2020 May 28.
4
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).
Cancer Res. 2020 Mar 1;80(5):1210-1218. doi: 10.1158/0008-5472.CAN-19-2850. Epub 2020 Jan 13.
5
Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.
JAMA. 2020 Jan 7;323(1):49-59. doi: 10.1001/jama.2019.20079.
6
Predictors of survival trajectories among women with epithelial ovarian cancer.
Gynecol Oncol. 2020 Feb;156(2):459-466. doi: 10.1016/j.ygyno.2019.12.011. Epub 2019 Dec 12.
7
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.
Cancer Res. 2019 Oct 15;79(20):5442-5451. doi: 10.1158/0008-5472.CAN-19-1554. Epub 2019 Aug 28.
8
Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity.
Clin Cancer Res. 2019 Oct 1;25(19):5937-5946. doi: 10.1158/1078-0432.CCR-18-3720. Epub 2019 May 29.
9
Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
10
Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
J Pathol. 2019 May;248(1):41-50. doi: 10.1002/path.5219. Epub 2019 Feb 15.
Zotero 插件